Arcturus therapeutics holdings inc. (ARCT)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Sep'18Jun'18
Collaboration revenue

19,085

20,789

21,244

20,312

0

0

0

Operating expenses:
Research and development, net

34,233

33,640

25,615

22,787

0

0

0

General and administrative

13,319

12,662

14,681

19,033

0

0

0

Total operating expenses

47,552

46,302

40,296

41,820

0

0

0

Loss from operations

-28,467

-25,513

-19,052

-21,508

0

0

0

Loss from equity-method investment

93

-32

-32

-382

0

0

0

Finance expense, net

-510

-446

-171

118

0

0

0

Net loss

-28,884

-25,991

-19,255

-21,772

0

0

0

Net loss per share, basic and diluted

-0.67

-0.84

-0.56

-0.07

-0.68

-0.42

-0.99

Weighted-average shares outstanding, basic and diluted

14,521

14,568

13,201

10,412

10,095

10,093

10,057

Comprehensive loss:
Net loss

-28,884

-25,991

-19,255

-21,772

0

0

0

Unrealized gain on short-term investments

-

-

-

-

-

0

0

Comprehensive loss

-28,884

-25,991

-19,253

-21,763

0

0

0